The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
Selinexor Xpovio®
is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor is used in the treatment of multiple myeloma.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
Selinexor Xpovio®
is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor is used in the treatment of multiple myeloma.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
Selinexor Xpovio®
is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor is used in the treatment of multiple myeloma.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy
SELINEXOR FOR LENALIDOMIDE-REFRACTORY PATIENTSSparkCures Verified Accurate, up-to-date information. Learn more
A Phase II Study of Selinexor In Addition to Lenalidomide for Consolidation and Maintenance Treatment After...
SELINEXOR IN ADDITION TO LENALIDOMIDEPersonalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
PERSONALIZED SELINEXOR-BASED THERAPYSelinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refracto...
SELINEXOR COMBINATION THERAPYThe following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
A Phase II Study of Selinexor In Addition to Lenalidomide for Consolidation and Maintenance Treatment After...
SELINEXOR IN ADDITION TO LENALIDOMIDEThe following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
SparkCures Verified Accurate, up-to-date information. Learn more
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
PERSONALIZED SELINEXOR-BASED THERAPYSelinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refracto...
SELINEXOR COMBINATION THERAPYThe following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy
SELINEXOR FOR LENALIDOMIDE-REFRACTORY PATIENTSSparkCures Verified Accurate, up-to-date information. Learn more
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
PERSONALIZED SELINEXOR-BASED THERAPYSelinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refracto...
SELINEXOR COMBINATION THERAPYThe following is a listing of clinical trials for patients with Smoldering Myeloma.